ArticleBMJ open2023

Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care).

Takahiro Osawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.